2015-2022 流感疫苗株重組抗原-環(huán)球風(fēng)云-資訊-生物在線

女人与狗锁死了视频大全|霍金死亡过程恐怖视频|无节社团简谱季免费观看|六间房直播大厅|中文字幕欧美另类精品|久久人人玩人妻潮喷内射人人|亚洲国产一区二区三区在线观看

2015-2022 流感疫苗株重組抗原

作者：北京義翹神州科技有限公司 2021-05-07T16:04 (訪問(wèn)量:37206)

流行性感冒是一種常見(jiàn)的季節(jié)性可傳染的呼吸道疾病，由流感病毒引起。目前，已鑒定的流感病毒有4類，包括A型，B型，C型和D型。其中，A型和B型流感病毒可引起大范圍的流行性感冒，因此也更加受到生物醫(yī)學(xué)界科學(xué)家們的關(guān)注。值得關(guān)注的是，以往的幾次全球性流感大流行基本都是由A型流感病毒引起的，比如Hong Kong flu (1968–1969)，H1N1/09 flu pandemic (2009–2010)分別由A/Hong Kong/1/1968 (H3N2) 和 A/California/04/09 (H1N1) 導(dǎo)致。

接種流感疫苗是預(yù)防流行性感冒的有效方法。每年WHO都會(huì)根據(jù)新分離出的毒株檢測(cè)數(shù)據(jù)以及上一個(gè)季節(jié)流感疫苗的性能選擇3-4種不同的流感毒株作為疫苗株。近幾十年，流感疫苗均為4價(jià)或者3價(jià)，可預(yù)防的流感包括1種H1N1、1種H3N2以及1種或者2種B型流感病毒（Yamagata 或/和 Victoria ）。



義翹神州ProVir病毒抗原庫(kù)中覆蓋了近600+流感病毒抗原，包括重組HA, NA, NP以及更多流感抗原，覆蓋了近些年WHO推薦的所有流感疫苗株，可用于檢測(cè)分析疫苗介導(dǎo)的抗體應(yīng)答反應(yīng)。除此之外，我們還開發(fā)了80余種流感病毒單克隆抗體試劑，可用于相關(guān)檢測(cè)試劑開發(fā)。
2021-2022流感疫苗株相關(guān)重組蛋白產(chǎn)品
A/Victoria/2570/2019 (H1N1)
Recommended for Egg-based (quadrivalent,trivalent) Vaccine
HA: 40787-V08H, 40787-V08H1
NA: 40785-V08B
NP: 40774-V08B		 A/Wisconsin/588/2019 (H1N1)
Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: 40787-V08H, 40787-V08H1
NA: 40785-V08B
NP: 40774-V08B
B/Washington/02/2019
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: 40722-V08H
NA: 40790-V08B
NP: 40755-V08B		 B/Phuket/3073/2013
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent) Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B
A/Cambodia/E0826360/2020 (H3N2)
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: 40789-V08H, 40789-V08H1
NA: 40784-V08B
NP: 40778-V08B (Under Development)
2020-2021流感疫苗株相關(guān)重組蛋白產(chǎn)品
A/Guangdong-Maonan/SWL1536/2019 (H1N1)
Recommended for Egg-based (quadrivalent, trivalent) Vaccine
HA: 40717-V08H
NP: 40723-V08B		 A/Hong Kong/2671/2019 (H3N2)
Recommended for Egg-based (quadrivalent, trivalent) Vaccine
HA: 40721-V08H
NP: 40753-V08B
A/Hawaii/70/2019 (H1N1)
Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: 40717-V08H
NP: 40724-V08B		 A/Hong Kong/45/2019 (H3N2)
Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA:40765-V08H (Under Development)
NP: 40754-V08B
B/Phuket/3073/2013
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent) Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B		 B/Washington/02/2019
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: 40722-V08H
NP: 40755-V08B
2019-2020流感疫苗株相關(guān)重組蛋白產(chǎn)品
A/Brisbane/02/2018 (H1N1)
Recommended for Egg-based (quadrivalent) Vaccine
HA: 40719-V08H
NP: 40776-V08B		 A/Kansas/14/2017 (H3N2)
Recommended for Egg-based (quadrivalent) Vaccine
HA: 40720-V08H
NP: 40779-V08B
B/Phuket/3073/2013
Recommended for Egg-based (quadrivalent) Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B		 B/Colorado/06/2017
Recommended for Egg-based (quadrivalent); trivalent Vaccine
HA: 40581-V08H
NP: 40782-V08B (Under Development)
2018-2019流感疫苗株相關(guān)重組蛋白產(chǎn)品
A/Michigan/45/2015 (H1N1)
Recommended for quadrivalent Vaccine
HA: 40567-V08H1
NA: 40568-V08B
NP: 40777-V08B		 A/Singapore/INFIMH-16-0019/2016 (H3N2)
Recommended for quadrivalent Vaccine
HA: 40580-V08H
NP: 40779-V08B
B/Colorado/06/2017
Recommended for quadrivalent; trivalent Vaccine
HA: 40581-V08H
NP: 40782-V08B (Under Development)		 B/Phuket/3073/2013
Recommended for quadrivalent Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B
2017-2018流感疫苗株相關(guān)重組蛋白產(chǎn)品
A/Michigan/45/2015 (H1N1)
Recommended for trivalent Vaccine
HA: 40567-V08H1
NA: 40568-V08B
NP: 40777-V08B		 A/Hong Kong/4801/2014 (H3N2)
Recommended for trivalent Vaccine
HA: 40555-V08B
NA: 40569-V08B
NP: 40781-V08B
B/Brisbane/60/2008
Recommended for trivalent Vaccine
HA: 40016-V08B
NA: 40203-VNAHC
NP: 40783-V08B (Under Development)		 B/Phuket/3073/2013
Recommended for quadrivalent Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B
2016-2017流感疫苗株相關(guān)重組蛋白產(chǎn)品
A/California/7/2009 (H1N1)
Recommended for trivalent Vaccine
HA: 11085-V08B
NP: 40205-V08B		 A/Hong Kong/4801/2014 (H3N2)
Recommended for trivalent Vaccine
HA: 40555-V08B
NA: 40569-V08B
NP: 40781-V08B
B/Brisbane/60/2008
Recommended for trivalent Vaccine
HA: 40016-V08B
NA: 40203-VNAHC
NP: 40783-V08B (Under Development)		 B/Phuket/3073/2013
Recommended for trivalent Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B
2015-2016流感疫苗株相關(guān)重組蛋白產(chǎn)品
A/California/7/2009 (H1N1)
Recommended for trivalent Vaccine
HA: 11085-V08B
NP: 40205-V08B		 A/Switzerland/9715293/2013 (H3N2)
Recommended for trivalent Vaccine
HA: 40497-V08B
NP: 40499-V08B
B/Brisbane/60/2008
Recommended for quadrivalent Vaccine
HA: 40016-V08B
NA: 40203-VNAHC
NP: 40783-V08B (Under Development)		 B/Phuket/3073/2013
Recommended for trivalent Vaccine
HA: 40498-V08B
NA: 40502-V07B
NP: 40500-V08B
北京義翹神州科技有限公司 商家主頁(yè)

地 址： 北京亦莊東區(qū)科創(chuàng)十街18號(hào)院9號(hào)樓306室

聯(lián)系人： 客服部

電 話： 400-890-9989

傳 真： 010-50911666

Email：marketing@sinobiological.cn

相關(guān)咨詢

義翹神州與鎂伽達(dá)成深度戰(zhàn)略合作，全自動(dòng)質(zhì)粒構(gòu)建系統(tǒng)項(xiàng)目正式落地 (2023-04-20T08:30 瀏覽數(shù):33788)

義翹神州年中促銷活動(dòng)正式開始啦 (2022-07-01T16:56 瀏覽數(shù):34514)

義翹神州成功開發(fā)“奧密克戎”變異株重組蛋白 (2021-12-03T09:57 瀏覽數(shù):32427)

第五屆青科會(huì)廣發(fā)“英雄令”，誠(chéng)邀麒麟之才共襄科研賽事 (2021-09-16T14:51 瀏覽數(shù):32276)

義翹神州成功上市，開啟發(fā)展新征程 (2021-08-16T11:05 瀏覽數(shù):40699)

可識(shí)別多種抗原的流感廣譜抗體 (2021-08-02T10:05 瀏覽數(shù):32913)

1000+重組病毒抗原庫(kù)：ProVir (2021-06-25T15:41 瀏覽數(shù):40476)

突變株不斷出現(xiàn)，我們應(yīng)該如何應(yīng)對(duì) (2021-06-02T14:46 瀏覽數(shù):29398)

超全的新冠病毒突變蛋白試劑庫(kù) (2021-06-02T14:33 瀏覽數(shù):32639)

2015-2022 流感疫苗株重組抗原 (2021-05-07T16:04 瀏覽數(shù):37206)

ADVERTISEMENT